Total Ischemic Event Reduction with Rivaroxaban after Peripheral Arterial Revascularization in the VOYAGER PAD Trial
Sub-analysis (n=6564) found rivaroxaban plus aspirin reduced total primary events (acute limb ischemia, major amputation, MI, ischemic stroke, or CV death; HR 0.86,95% CI 0.75-0.98; p=0.02) and peripheral revascularizations and VTE (0.86; 0.79-0.95; p=0.003) vs aspirin alone.
Source:
American Journal of Cardiology
SPS commentary:
In patients with symptomatic peripheral arterial revascularization undergoing lower extremity revascularization, an estimated 4.4 primary and 12.5 vascular events/100 participants were avoided with rivaroxaban over three years.
There was an increased rate of major bleeding, though this was not statistically significant (2.65% vs. 1.87%, respectively; HR=1.43, 95% CI, 0.97–2.10; p=0.07).